Credit: ARS Pharmaceuticals; denismagilov/Adobe Stock
The maker of a new prescription drug product for people with life-threatening allergies is using copayment coupons to build early sales.
ARS Pharmaceuticals recently introduced the Neffy nasal spray delivery device. The product that can free patients facing anaphylactic shock, or allergy-related problems with breathing, from having to use EpiPens to inject themselves with epinephrine.
|
Related: GlaxoSmithKline & other drugmakers delist FDA patents, after FTC 'Big Pharma' scrutiny
The full cost of the product is about $750 for a two-spray package, according to Drugs.com.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Allison Bell
Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.
